Paclitaxel Injection Market Report 2024 Latest Insights, Growth Rate, Future Trends And Forecast | Key Players : Pfizer Inc., Bristol-Myers Squibb Company, Fresenius Kabi Oncology Ltd., Abbott Laboratories

"The paclitaxel injection market size has grown rapidly in recent years. It will grow from $5.26 billion in 2023 to $6.02 billion in 2024 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to clinical research and trials, increasing incidence of cancer, patient awareness and education, globalization of pharmaceutical industry.

The paclitaxel injection market size is expected to see rapid growth in the next few years. It will grow to $9.85 billion in 2028 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to personalized medicine approaches, biosimilar development, rising cancer burden in aging population, advancements in drug delivery systems, healthcare policy changes. Major trends in the forecast period include integration of ai in oncology, telemedicine and remote healthcare services, technological innovations in drug delivery, integration of drug delivery technologies, rise of biosimilars.

Market Overview -
Paclitaxel injection is a injection used in cancer treatment as a chemotherapy drug. It is administered as an infusion into a vein in a hospital or clinic by a specially trained healthcare professional. It works by disrupting the division and growth of cancer cells, leading to their destruction.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13211&type=smp

Rising Incidence Of Breast Cancer Fuels Growth In The Paclitaxel Injection Market
The growing incidence of breast cancer is expected to propel the growth of the paclitaxel injection market going forward. Breast cancer is a disease in which cells in the breast grow abnormally and can form a tumor, a lump of tissue that spreads to other parts of the body. Paclitaxel injection is a chemotherapy drug used to treat breast cancer by binding to the microtubules, which are structures that help to hold the cancer cells together, stopping the growth of cancer cells. For instance, in January 2023, according to the American Cancer Society, a US-based cancer-fighting organization, it is estimated that around 297,790 new cases of invasive breast cancer are expected to be diagnosed in the US, and 43,700 deaths are expected to occur from breast cancer in 2023. Therefore, the growing incidence of breast cancer is driving the growth of the paclitaxel injection market.

Competitive Landscape -
Major companies operating in the paclitaxel injection market report are Pfizer Inc., Bristol-Myers Squibb Company, Fresenius Kabi Oncology Ltd., Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz International GmbH, Hospira Inc., Dr. Reddy's Laboratories Ltd., Apotex Inc., Intas Pharmaceuticals Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Ltd., Luye Pharma Group, Biological E Limited, Alembic Pharmaceuticals Limited, Khandelwal Laboratories Pvt. Ltd., Gland Pharma Limited, Abraxis Bio Science Inc., Novasep Holding SAS, Sagent Pharmaceuticals Inc., Hainan Haiyao Co Ltd., Accord Healthcare Ltd., Natco Pharma Limited, Strides Pharma Science Limited, Panacea Biotec Ltd., American Regent Inc., MSN Laboratories Pvt Ltd., Hetero Drugs Ltd.

Innovative Advancements In Paclitaxel Injection Market
Major companies operating in the paclitaxel injection market are developing innovative products with advanced materials, such as protein-bound particles, to provide reliable services to the consumers. Protein-bound particles (PBPs) are a drug delivery system that uses albumin, a naturally occurring protein in the blood, to bind to a drug. For instance, in April 2022, Apotex Corp, a US-based pharmaceutical company, launched Paclitaxel protein-bound particles for injection (albumin-bound), a generic version of Abraxanes for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, and the treatment of metastatic breast cancer. It is administered as an intravenous infusion and launched by American Regent, Inc. as an alternative to Abraxane.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/paclitaxel-injection-global-market-report

Key Segments -
The paclitaxel injection market covered in this report is segmented -
1) By Type: Natural Paclitaxel, Semi-synthetic Paclitaxel
2) By Drug Strength: 10mg/mL, 20mg/mL, 30mg/mL
3) By Indication: Breast Cancer, Prostate Cancer, Testicular Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Other Indications
4) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
5) By End User: Hospitals, Clinics, Cancer Research Institute

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model "

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.